Opioid Dependence Treatment Therapies in Pregnancy

Pregnancy Clinical Trial

Official title:

A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03098407
• Other study ID #: PRO16020403
• Secondary ID: 1K23DA038789-01A
• Status: Completed
• Phase: N/A
• Start date: April 20, 2017
• Est. completion date: October 5, 2020

Study information

• Verified date: November 2020
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The incidence of opioid dependence in pregnancy increased over the last decade from 1.2 to 5.8 per 1,000 hospital births per year.1 While methadone is the current, standard treatment for opioid dependent (OD) pregnant women, buprenorphine recently emerged as an alternative. In a recent clinical trial (MOTHER), buprenorphine was associated with superior neonatal outcomes such as shorter duration of treatment for neonatal abstinence syndrome (NAS) compared to methadone. However, buprenorphine was also associated with greater study discontinuation (33% vs. 18%) and illicit opioid use (33% vs. 23%) compared to methadone. Treatment dropout often leads to relapse and resumption of high-risk behaviors, overshadowing any short-term improvement in neonatal outcomes. Therefore, The goal of this K23 proposal is to conduct a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone programs for the treatment of OD pregnant women.

A pilot study is critical to develop the outcome measures, assessment tools and participant tracking techniques necessary for a future, large-scale comparative effectiveness clinical trial. An examination of feasibility and acceptability will also allow use to characterize the subpopulations of OD pregnant women willing to participate in treatment randomization, identify patient and provider characteristics associated with established treatment preferences and inform the development of strategies to improve participation and enhance the generalizability of the future large-scale clinical trial.

Description:

Objective:

The goal of this proposal is to conduct a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone programs for the treatment of opioid dependent pregnant women.

Specific Aims:

Aim 1: Evaluate the feasibility of conducting a randomized study comparing office-based buprenorphine vs. federally licensed methadone programs for the treatment of OD pregnant women. OD pregnant women (n=50) will be randomized (1:1) to office-based buprenorphine vs. a federally licensed methadone program. Feasibility will be assessed by measuring the proportion of OD pregnant women who are eligible, who enroll, who remain in the study and by the ability to monitor treatment program factors (e.g. compliance with treatment provider/facility visits, counseling sessions, prenatal care visits, social services involvement) and maternal treatment outcomes such as treatment retention, illicit drug use and HIV risk behavior.

Aim 2: Describe the perspectives of OD pregnant women and their providers regarding buprenorphine vs. methadone for the treatment of opioid dependence in pregnancy. Study acceptability will be assessed by conducting qualitative semi-structured interviews with three groups: (1) pilot participants to determine their satisfaction with the assigned treatment program and identify mismatches between treatment program services and participants' needs; (2) prenatal care and opioid treatment providers to identify ways to improve the treatment process in pregnancy and to suggest ideas for care coordination; (3) OD pregnant women who are ineligible or who choose not to participate in the pilot trial will also be asked to participate in an interview to gain a broader perspective of attitudes and perspectives regarding opioid treatment programs in pregnancy.

Aim 3: Identify barriers and facilitators to treatment retention in the postpartum period and identify key functional outcomes relevant to reductions in illicit drug use during pregnancy. Illicit drug use relapse is most common in the immediate postpartum period when stresses associated with motherhood are the greatest. Therefore, pilot participants will be followed at 3, 6, 9 and 12 weeks postpartum to identify barriers and facilitators specific to the postpartum period that may impact treatment retention. The relationship between postpartum treatment retention and maternal functional outcomes will also be explored (e.g. breastfeeding, postpartum depression, motherhood satisfaction, infant custody, employment, and criminality).

Background:

The incidence of opioid dependence in pregnancy increased over the last decade from 1.2 to 5.8 per 1,000 hospital births per year. While methadone is the current, standard treatment for opioid dependent (OD) pregnant women, buprenorphine recently emerged as an alternative. In a recent clinical trial (MOTHER), buprenorphine was associated with superior neonatal outcomes such as shorter duration of treatment for neonatal abstinence syndrome (NAS) compared to methadone. However, buprenorphine was also associated with greater study discontinuation (33% vs. 18%) and illicit opioid use (33% vs. 23%) compared to methadone. Treatment dropout often leads to relapse and resumption of high-risk behaviors, overshadowing any short-term improvement in neonatal outcomes. Therefore, the next research question that emerges is which is the most effective treatment (buprenorphine vs. methadone) for a particular patient during pregnancy?

In clinical settings, differences in maternal characteristics, treatment program structure and patient and provider preferences may surpass the impact of pharmacology on maternal treatment outcomes (treatment retention, illicit drug use, HIV risk behavior). Buprenorphine is dispensed in office-based settings by a variety of providers and with less regulatory oversight than methadone. Methadone is dispensed from federally licensed facilities that often incorporate counseling and support services into treatment protocols. Successful office-based treatment relies on shared power and responsibility, close patient-provider relationships and careful attention to psychosocial co-morbidities. Failure to match patient problem severity to differences in treatment program structure may contribute to adverse maternal outcomes. Therefore, to understand the comparative effectiveness of buprenorphine vs. methadone in pregnancy, the impact of patient problem severity and treatment program structure on maternal (vs. neonatal) outcomes must be compared.

Significance:

Findings from this project will provide the preliminary data to support a comparative effectiveness clinical trial designed to compare the impact of office-based buprenorphine vs. federally licensed methadone programs on maternal treatment and postpartum functional outcomes in OD women. The ultimate goal of this line of research is develop evidence-based clinical guidelines to guide provider decision-making regarding the most effective treatment (buprenorphine vs. methadone) for a particular patient during pregnancy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: October 5, 2020
• Est. primary completion date: October 9, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pregnant women 18+ years old, with a singleton pregnancy = 28 weeks gestation confirmed by ultrasound, who meet Diagnostic and Statistical Manual-IV criteria for opioid dependence confirmed by urine drug screen (UDS), who are interested in opioid maintenance treatment and plan to receive prenatal care and deliver at Magee Womens Hospital (MWH) will be recruited.

Exclusion Criteria:

• (1) active, current dependence on benzodiazepines or alcohol

• (2) acute severe psychiatric condition in need of immediate treatment (e.g. suicidal ideations)

• (3) pending or legal action that could prohibit or interfere with participation (e.g. incarceration)

• (4) current, established treatment with methadone or buprenorphine. Exclusion criteria are based on the Substance Abuse and Mental Health Services Administration (SAMHSA) recommendations for office-based buprenorphine use.

Related Conditions & MeSH terms

• Opioid-Related Disorders
• Pregnancy

Intervention

Drug:
• Buprenorphine
This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
• Methadone
This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.

Locations

Country	Name	City	State
United States	Magee-Womens Hospital of UPMC	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Pittsburgh	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (61)

Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009 Sep;201(3):326.e1-6. doi: 10.1016/j.ajog.2009.05.052. Epub 2009 Jul 24. — View Citation

Andersen R, Chen MS, Aday LA, Cornelius L. Health status and medical care utilization. Health Aff (Millwood). 1987 Spring;6(1):136-56. — View Citation

Ashley OS, Marsden ME, Brady TM. Effectiveness of substance abuse treatment programming for women: a review. Am J Drug Alcohol Abuse. 2003;29(1):19-53. Review. — View Citation

Bandstra ES, Morrow CE, Mansoor E, Accornero VH. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis. 2010 Apr;29(2):245-58. doi: 10.1080/10550881003684871. Review. — View Citation

Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE, Hansen H, O'Connor PG, Schottenfeld RS, Fiellin DA. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009 Feb;24(2):218-25. doi: 10.1007/s11606-008-0881-9. Epub 2008 Dec 17. — View Citation

Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, Martin PR. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010 Sep-Oct;19(5):416-21. doi: 10.1111/j.1521-0391.2010.00064.x. — View Citation

Benoit E, Young R, Magura S, Staines GL. The impact of welfare reform on methadone treatment: policy lessons from service providers in New York city. Subst Use Misuse. 2004;39(13-14):2355-90. — View Citation

Binder T, Vavrinková B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett. 2008 Feb;29(1):80-6. — View Citation

Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010 Sep;29(5):551-6. doi: 10.1111/j.1465-3362.2010.00176.x. — View Citation

Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse. 1999 Jun;34(8):1137-65. — View Citation

Chisolm MS, Tuten M, Brigham EC, Strain EC, Jones HE. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict. 2009 Sep-Oct;18(5):422-9. doi: 10.3109/10550490903077721. — View Citation

Cleary BJ, Donnelly JM, Strawbridge JD, Gallagher PJ, Fahey T, White MJ, Murphy DJ. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011 Feb;204(2):139.e1-9. doi: 10.1016/j.ajog.2010.10.004. Epub 2010 Dec 8. — View Citation

Creanga AA, Sabel JC, Ko JY, Wasserman CR, Shapiro-Mendoza CK, Taylor P, Barfield W, Cawthon L, Paulozzi LJ. Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol. 2012 May;119(5):924-33. doi: 10.1097/AOG.0b013e31824ea276. — View Citation

Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998 Nov;92(5):854-8. — View Citation

Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res. 2012 Mar;1(2):181-194. — View Citation

Etter JF. A comparison of the content-, construct- and predictive validity of the cigarette dependence scale and the Fagerström test for nicotine dependence. Drug Alcohol Depend. 2005 Mar 7;77(3):259-68. — View Citation

Feske U, Tarter RE, Kirisci L, Pilkonis PA. Borderline personality and substance use in women. Am J Addict. 2006 Mar-Apr;15(2):131-7. — View Citation

Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004 Sep;27(2):153-9. Review. — View Citation

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302. — View Citation

Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007 Jun;1(2):62-7. doi: 10.1097/ADM.0b013e3180473c11. — View Citation

Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stühlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999 Sep;94(9):1337-47. — View Citation

Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006 Feb;101(2):275-81. — View Citation

Goodman D. Buprenorphine for the treatment of perinatal opioid dependence: pharmacology and implications for antepartum, intrapartum, and postpartum care. J Midwifery Womens Health. 2011 May-Jun;56(3):240-7. doi: 10.1111/j.1542-2011.2011.00049.x. Review. — View Citation

Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013 Jul;40(3):367-77. doi: 10.1007/s11414-013-9341-3. — View Citation

Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, Coyle MG, Kaltenbach K. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug Alcohol Depend. 2013 Sep 1;132(1-2):329-34. doi: 10.1016/j.drugalcdep.2013.02.031. Epub 2013 Mar 21. — View Citation

Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus. 2007 Jun;28(2):3-8. doi: 10.1300/J465v28n02_02. — View Citation

Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009 Jan 1;99(1-3):132-40. doi: 10.1016/j.drugalcdep.2008.07.013. Epub 2008 Sep 19. — View Citation

Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, Starer J, Terplan M, Thorp JM Jr, Walsh J, Creanga AA. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014 Apr;210(4):302-310. doi: 10.1016/j.ajog.2013.10.010. Epub 2013 Oct 10. — View Citation

Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012 Apr 16;72(6):747-57. doi: 10.2165/11632820-000000000-00000. Review. — View Citation

Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov;107 Suppl 1:5-27. doi: 10.1111/j.1360-0443.2012.04035.x. Review. — View Citation

Jones HE, Heil SH, O'Grady KE, Martin PR, Kaltenbach K, Coyle MG, Stine SM, Selby P, Arria AM, Fischer G. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse. 2009;35(5):375-80. doi: 10.1080/00952990903125235. — View Citation

Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005 Jul;79(1):1-10. — View Citation

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359. — View Citation

Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010 Apr;29(2):175-91. doi: 10.1080/10550881003684723. — View Citation

Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care. J Addict Med. 2010 Dec;4(4):204-10. doi: 10.1097/ADM.0b013e3181cc9610. — View Citation

Krans EE, Cochran G, Bogen DL. Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol. 2015 Jun;58(2):370-9. doi: 10.1097/GRF.0000000000000098. — View Citation

Krans EE, Davis MM, Palladino CL. Disparate patterns of prenatal care utilization stratified by medical and psychosocial risk. Matern Child Health J. 2013 May;17(4):639-45. doi: 10.1007/s10995-012-1040-9. — View Citation

Krans EE, Davis MM, Schwarz EB. Psychosocial risk, prenatal counseling and maternal behavior: findings from PRAMS, 2004-2008. Am J Obstet Gynecol. 2013 Feb;208(2):141.e1-7. doi: 10.1016/j.ajog.2012.11.017. Epub 2012 Nov 15. — View Citation

Krans EE, Davis MM. Preventing Low Birthweight: 25 years, prenatal risk, and the failure to reinvent prenatal care. Am J Obstet Gynecol. 2012 May;206(5):398-403. doi: 10.1016/j.ajog.2011.06.082. Epub 2011 Jun 29. — View Citation

Krans EE, Moloci NM, Housey MT, Davis MM. Impact of psychosocial risk factors on prenatal care delivery: a national provider survey. Matern Child Health J. 2014 Dec;18(10):2362-70. doi: 10.1007/s10995-014-1476-1. — View Citation

Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011 Oct;67(10):1053-9. doi: 10.1007/s00228-011-1049-9. Epub 2011 May 3. — View Citation

Latt NC, Spencer JD, Beeby PJ, McCaughan GW, Saunders JB, Collins E, Cossart YE. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000 Feb;15(2):175-81. — View Citation

Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977 Jan 15;127(2):199-201. — View Citation

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. doi: 10.1002/14651858.CD002207.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD002207. — View Citation

McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213. — View Citation

Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015 Mar-Apr;9(2):81-6. doi: 10.1097/ADM.0000000000000092. — View Citation

Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, Schottenfeld RS. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007 Apr;22(4):527-30. — View Citation

Morgenstern J, Hogue A, Dauber S, Dasaro C, McKay JR. A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries. J Consult Clin Psychol. 2009 Apr;77(2):257-69. doi: 10.1037/a0014489. — View Citation

Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009 Nov 1;105(1-2):83-8. doi: 10.1016/j.drugalcdep.2009.06.015. Epub 2009 Jul 21. Erratum in: Drug Alcohol Depend. 2011 Jan 15;113(2-3):252. — View Citation

Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30. — View Citation

Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord. 2007 Apr;99(1-3):213-20. Epub 2006 Oct 19. — View Citation

Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013 Jul;74(4):605-13. — View Citation

Roman PM, Abraham AJ, Rothrauff TC, Knudsen HK. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S44-52. doi: 10.1016/j.jsat.2009.12.008. — View Citation

Rowan-Szal GA, Chatham LR, Joe GW, Simpson DD. Services provided during methadone treatment. A gender comparison. J Subst Abuse Treat. 2000 Jul;19(1):7-14. — View Citation

Simpson DD. A conceptual framework for drug treatment process and outcomes. J Subst Abuse Treat. 2004 Sep;27(2):99-121. — View Citation

Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013 Sep;209(3):267.e1-5. doi: 10.1016/j.ajog.2013.05.026. Epub 2013 May 29. — View Citation

Stine SM, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Fischer G, Arria AM, Selby P, Jones HE. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse. 2009;35(6):429-33. doi: 10.3109/00952990903374080. — View Citation

Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743. — View Citation

Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358-63. doi: 10.1080/00952990903108231. Erratum in: Am J Drug Alcohol Abuse. 2010 Sep;36(5):304. — View Citation

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010 Jul;39(1):51-7. doi: 10.1016/j.jsat.2010.04.001. — View Citation

Winhusen T, Wilder C, Wexelblatt SL, Theobald J, Hall ES, Lewis D, Van Hook J, Marcotte M. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. Contemp Clin Trials. 2014 Sep;39(1):158-65. doi: 10.1016/j.cct.2014.08.009. Epub 2014 Aug 23. — View Citation

* Note: There are 61 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants who are recruited, enrolled, retained, and who complete the study.	evaluate a minimum of 9 OD pregnant women per month for possible participation and enrollment, randomize a minimum of 4 participants per month to office-based buprenorphine (PRC) or methadone treatment facility (NATP) for a total of 50 participants over a 12 month enrollment period, retain = 80% of randomized participants until 12 weeks postpartum, and maintain < 5% of incomplete data.	12 Months